PE20170937A1 - Nuevos activadores de la guanilato ciclasa soluble y su uso - Google Patents

Nuevos activadores de la guanilato ciclasa soluble y su uso

Info

Publication number
PE20170937A1
PE20170937A1 PE2017000478A PE2017000478A PE20170937A1 PE 20170937 A1 PE20170937 A1 PE 20170937A1 PE 2017000478 A PE2017000478 A PE 2017000478A PE 2017000478 A PE2017000478 A PE 2017000478A PE 20170937 A1 PE20170937 A1 PE 20170937A1
Authority
PE
Peru
Prior art keywords
alkyl
piperidine
refers
soluble
cyclase
Prior art date
Application number
PE2017000478A
Other languages
English (en)
Spanish (es)
Inventor
Anne Marie Jeanne Bouillot
Nerina Dodic
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of PE20170937A1 publication Critical patent/PE20170937A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
PE2017000478A 2014-09-19 2015-09-18 Nuevos activadores de la guanilato ciclasa soluble y su uso PE20170937A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462052537P 2014-09-19 2014-09-19

Publications (1)

Publication Number Publication Date
PE20170937A1 true PE20170937A1 (es) 2017-07-13

Family

ID=54238488

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000478A PE20170937A1 (es) 2014-09-19 2015-09-18 Nuevos activadores de la guanilato ciclasa soluble y su uso

Country Status (21)

Country Link
US (2) US9938260B2 (https=)
EP (1) EP3194384A1 (https=)
JP (3) JP6678656B2 (https=)
KR (1) KR20170054508A (https=)
CN (1) CN106687456B (https=)
AU (1) AU2015319724B2 (https=)
BR (1) BR112017005660A2 (https=)
CA (1) CA2961745A1 (https=)
CL (1) CL2017000640A1 (https=)
CO (1) CO2017002506A2 (https=)
CR (1) CR20170102A (https=)
DO (1) DOP2017000073A (https=)
EA (1) EA033697B1 (https=)
IL (1) IL251094A0 (https=)
MA (1) MA40583A (https=)
MX (1) MX2017003621A (https=)
PE (1) PE20170937A1 (https=)
PH (1) PH12017500481A1 (https=)
SG (1) SG11201701915TA (https=)
WO (1) WO2016042536A1 (https=)
ZA (1) ZA201701835B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102352388B1 (ko) 2014-02-06 2022-01-17 헵테얼즈 테라퓨틱스 리미티드 무스카린성 m1 수용체 및/또는 m4 수용체 작용제로서 바이사이클릭 아자 화합물
MA39484A (fr) 2014-09-19 2016-03-24 Bayer Pharma AG Indazoles à substituants benzyle utilisés comme inhibiteurs de bub1
EA033697B1 (ru) * 2014-09-19 2019-11-18 Glaxosmithkline Ip Dev Ltd Активаторы растворимой гуанилатциклазы и их применение
CA3039735A1 (en) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Combination containing sgc activators and mineralocorticoid receptor antagonists
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
JP7314173B2 (ja) 2018-04-30 2023-07-25 バイエル アクチェンゲゼルシャフト 認知障害の治療のためのsGC活性化薬及びsGC刺激薬の使用
CA3100096A1 (en) 2018-05-15 2019-11-21 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
EP3574905A1 (en) 2018-05-30 2019-12-04 Adverio Pharma GmbH Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group
EP3911675A1 (en) 2019-01-17 2021-11-24 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
EP4536205A1 (en) 2022-06-09 2025-04-16 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602143A (en) 1994-12-08 1997-02-11 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
TWI409081B (zh) * 2006-11-09 2013-09-21 Alcon Res Ltd 用於藥物輸送之水不溶性聚合物基質
PE20091258A1 (es) 2007-12-03 2009-09-12 Smithkline Beecham Corp Derivados de piridina como activadores de la guanilato ciclasa soluble
WO2010015653A1 (en) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
CN102414194A (zh) 2009-02-26 2012-04-11 默沙东公司 可溶性鸟苷酸环化酶激活剂
DE102009012314A1 (de) * 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
JP5636296B2 (ja) 2011-01-20 2014-12-03 公益財団法人微生物化学研究会 塩分含有有機廃液処理剤、並びに、塩分濃度低下剤、塩分含有有機廃液の処理方法、及び包括固定担体
EA033697B1 (ru) * 2014-09-19 2019-11-18 Glaxosmithkline Ip Dev Ltd Активаторы растворимой гуанилатциклазы и их применение

Also Published As

Publication number Publication date
CA2961745A1 (en) 2016-03-24
CN106687456B (zh) 2019-12-03
IL251094A0 (en) 2017-04-30
JP2017527602A (ja) 2017-09-21
AU2015319724A1 (en) 2017-04-06
JP2020105189A (ja) 2020-07-09
BR112017005660A2 (pt) 2017-12-19
PH12017500481A1 (en) 2017-08-07
US20180194756A1 (en) 2018-07-12
EA033697B1 (ru) 2019-11-18
MA40583A (fr) 2016-03-24
EP3194384A1 (en) 2017-07-26
ZA201701835B (en) 2018-12-19
WO2016042536A1 (en) 2016-03-24
SG11201701915TA (en) 2017-04-27
CL2017000640A1 (es) 2017-10-06
EA201790655A1 (ru) 2017-08-31
CO2017002506A2 (es) 2017-07-28
US20170305888A1 (en) 2017-10-26
MX2017003621A (es) 2017-07-14
AU2015319724B2 (en) 2018-05-10
KR20170054508A (ko) 2017-05-17
CN106687456A (zh) 2017-05-17
CR20170102A (es) 2017-07-17
US10472350B2 (en) 2019-11-12
JP6908747B2 (ja) 2021-07-28
US9938260B2 (en) 2018-04-10
JP6678656B2 (ja) 2020-04-08
DOP2017000073A (es) 2017-04-16
JP2021155450A (ja) 2021-10-07

Similar Documents

Publication Publication Date Title
PE20170937A1 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
PE20170697A1 (es) Indazoles sustituidos con benzilo como inhibidores de bub1
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
PE20141691A1 (es) Compuestos con actividad nematicida
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20170326A1 (es) Herbicidas de piridazinona
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
AR061644A1 (es) Derivados de benzofurano
PE20120937A1 (es) Compuestos derivados de quinolina y quinoxalina como agentes antivirales
PE20180227A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20180508A1 (es) Amidas heterociclicas como inhibidores de quinasa
PE20141583A1 (es) Nuevos derivados de piridina
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
PE20191142A1 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
PE20130155A1 (es) Derivados de ariletinilo
PE20161552A1 (es) Compuestos de dihidroisoquinolinona sustituida
PE20200608A1 (es) Nuevos derivados de azaquinolina
PE20161073A1 (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
PE20161143A1 (es) Derivados de pirimidiniloxi benceno como herbicidas
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
AR082799A1 (es) Derivados de quinolina y quinoxalina como inhibidores de quinasa
PE20100087A1 (es) Compuestos y composiciones como inhibidores de cinasa
PE20091407A1 (es) Antagonistas de aminoalquilbifenilo n,n-disubstituidos de receptores de prostaglandina d2
PE20130009A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana